1268245-64-2Relevant academic research and scientific papers
Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists
Smalley, Terrence L.,Boggs, Sharon,Caravella, Justin A.,Chen, Lihong,Creech, Katrina L.,Deaton, David N.,Kaldor, Istvan,Parks, Derek J.
, p. 280 - 284 (2015/02/19)
The farnesoid X receptor (FXR) may play a crucial role in a number of metabolic diseases and, as such, could potentially serve as a target for the development of therapeutics as a treatment for those diseases. Previous work has described GW4064 as an FXR
NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS
-
Page/Page column 42; 44, (2011/04/13)
The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.
